FDA to Bio-Makers: Tell Us About Your Oopsy-Daisies in Production
Published Date: 2/25/2026
Notice
Summary
The FDA wants to hear from companies that make biological products and human tissues about how they report mistakes during manufacturing. They’re asking for feedback on updating the forms and rules to keep things clear and safe. If you’re involved in making these products, you’ve got until April 27, 2026, to share your thoughts—no extra costs, just a chance to help improve the process!
Analyzed Economic Effects
4 provisions identified: 2 benefits, 1 costs, 1 mixed.
Mandatory 45‑Day Deviation Reporting
If you manufacture biological products, blood products, or regulated human cells and tissues, you must report product deviations using Form FDA 3486 as soon as possible but no later than 45 calendar days after learning of a reportable event. FDA estimates an average 2 hours to complete each deviation report; there are 17,818 total annual responses and a total estimated 43,246.25 annual burden hours (an increase of 13,602.95 hours and 2,383 responses based on FY2024 data).
Addendum and Partial Electronic Filing Rules
CBER offers an electronic report option and a web‑based addendum (Form FDA 3486A) for reports that may lead to a recall; FDA estimates 5% of CBER reports (about 825 annual addendum responses) and 15 minutes to complete each addendum. CDER currently does not accept electronic filings, so submissions to CDER must be made by non‑electronic methods.
Public Comment Opportunity by April 27, 2026
FDA is asking companies and stakeholders involved in biological product and HCT/P manufacturing to submit comments on the proposed information collection by April 27, 2026, via regulations.gov or by mail. The notice explains how to submit confidential information and that comments filed electronically will be posted publicly.
No Capital or O&M Costs Claimed
FDA states there are no capital costs or operating and maintenance (O&M) costs associated with this information collection for respondents. The burden estimate covers only reporting time, not equipment or other capital expenses.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13140 — Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of Oxygenation
The FDA is officially putting the monitor for opioid-induced oxygen problems into a safer, easier-to-manage category called Class II. This change helps make sure the device works well and is safe, while also speeding up patient access to this important tech. The new rules took effect on June 30, 2026, and could lower costs and delays for companies making these monitors.
2026-13139 — Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of Hyperhidrosis
The FDA is officially classifying the skin patch that treats excessive sweating (hyperhidrosis) as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to this cool new treatment faster and safer, starting June 30, 2026. Companies making these patches will find it easier and less costly to bring their products to market.
2026-13005 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; New Animal Drugs for Minor Use and Minor Species
The FDA is asking for public feedback on their plan to keep collecting info about new animal drugs for rare uses and less common species. This affects drug makers who want special approval and incentives for these unique animal medicines. Comments are open until July 29, 2026, and the process helps keep these important drugs safe and available without extra costs.
2026-13006 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYALEV
The FDA has officially set the review period for the drug VYALEV, which helps the company extend its patent protection. This means the patent clock can be paused, giving the drug maker more time to sell VYALEV exclusively. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by late 2026.
2026-13101 — Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock Absorber
The FDA is officially classifying the medial knee implanted shock absorber as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to this innovative knee device faster and with confidence in its safety. The new classification is effective June 29, 2026, and could save time and money for makers and users alike.
Previous / Next Documents
Previous: 2026-03772 — Agency Information Collection Activities; Proposed Collection; Comment Request; Current Good Manufacturing Practice Regulations for Medicated Feeds
The FDA wants feedback on how medicated animal feed makers keep their records to make sure everything’s safe and up to date. This affects companies that produce medicated feeds, and they have until April 27, 2026, to share their thoughts. No big money changes yet, just a chance to improve how info is collected and stored.
Next: 2026-03774 — Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals
The FDA just got the green light from the Office of Management and Budget to keep collecting important info from food and drug businesses. This means rules about food safety, facility registration, and tracking shipments stay in place through 2028, helping protect everyone’s health without extra costs or delays. If you’re involved in food or drug industries, keep an eye on these updates to stay on track!